KPV vs BPC-157: Which for Gut Healing?

Key takeaways

• Neither KPV nor BPC-157 has a human trial for gut healing or any gut condition. BPC-157 has about 220 rodent papers, mostly from one laboratory, and three uncontrolled human pilots that are not about the gut; KPV has a handful of mouse colitis studies from three independent groups and no human study at all.
• Neither can be compounded by a US pharmacy as of October 2026. Both came off FDA's Category 2 list in April 2026, both were recommended 8-6-1 by FDA's advisory committee on July 23, 2026 over the objection of FDA's own staff, and no rule has followed for either.
• They work differently in animals: BPC-157 grows blood vessels and acts on nitric oxide, and has no identified receptor; KPV rides the PepT1 peptide transporter into gut and immune cells and switches off NF-kappa-B. Nothing is known about the two together, because no study of the combination exists.
• The 'BPC-157 + KPV' capsules and the KLOW injectable blend are seller inventions. Stacking two unstudied peptides doubles the unknowns and makes any reaction impossible to attribute.
• If you have ulcerative colitis or Crohn's disease, the honest answer to 'which one' is neither: the treatments with randomized trials are the ones a gastroenterologist prescribes, and both of these are research vials until FDA acts.

The direct answer: there is no evidence-based winner. Neither BPC-157 nor KPV has been tested in a human with ulcerative colitis, Crohn's disease, an ulcer, 'leaky gut' or any other gut condition; neither can be legally compounded in the United States; and both were recommended for FDA's compounding list by the same 8-6-1 committee vote on July 23, 2026, which FDA has not acted on (HPM 2026). What can be compared is the animal evidence, the mechanism, the products sellers actually ship and what FDA's reviewers said about each. Our KPV dosage chart handles the dose question for KPV; the BPC-157 profile handles it for BPC-157.

Side by side

What the evidence says in the gut, for each

BPC-157. The Zagreb group has published rodent gut data for thirty years: protection of the stomach lining from indomethacin, aspirin, diclofenac and alcohol, and healing of experimental colitis, fistulas, short bowel and anastomoses. The colocutaneous fistula study is representative. Rats with a surgically created fistula received BPC-157 at 10 mcg/kg or 10 ng/kg either in drinking water or by daily injection into the abdomen; both routes and both doses accelerated closure of the colon and skin defects, the effect survived blocking nitric oxide synthesis, sulfasalazine was only moderately effective and methylprednisolone made healing worse (Klicek 2008). The paper's title calls BPC-157 a peptide 'in clinical trials' for inflammatory bowel disease under the code PL 14736, and the group's 2012 review says the compound had by then been tested 'only' in Phase 2 (Sikiric 2012). No result of that program has ever been published, and a 2026 drug-development review counts fewer than 30 human subjects in the entire BPC-157 literature, all in uncontrolled pilots, with no human pharmacokinetics and no dosing rationale (Mateescu 2026). When FDA evaluated the ulcerative colitis nomination in July 2026, its staff found no adequate human data (Kelley Drye 2026). The same-effect-at-every-dose pattern (10 micrograms and 10 nanograms per kilogram doing the same thing) and the single-laboratory origin of most of the data are discussed in the BPC-157 profile.

KPV. The gut data are fewer, newer and spread across independent laboratories. The Emory study showed that KPV enters colon epithelial cells and T cells through PepT1, inhibits NF-kappa-B and MAP-kinase signaling at 10 nanomolar, and reduces both DSS and TNBS colitis in mice when added to drinking water at 100 micromolar (Dalmasso 2008). A Münster group found earlier recovery, faster weight regain and lower colonic myeloperoxidase in DSS colitis, recovery in a T-cell transfer model of chronic colitis, and survival of every KPV-treated mouse in a melanocortin-receptor-mutant strain that otherwise died of DSS colitis (Kannengiesser 2008). The Emory laboratory went on to show that colon-targeted nanoparticles deliver the effect at a fraction of the free-peptide amount and that KPV's protection against colitis-associated tumors disappears in mice without PepT1; the KPV profile covers those studies. There is no human study of KPV of any kind, and FDA's staff said so when it was reviewed (Kelley Drye 2026).

So the comparison on gut evidence is volume from one laboratory against a smaller, independently replicated set with a cleaner mechanism. Neither is a trial. For a person deciding whether to take one, the difference between 'hundreds of rat papers' and 'a dozen mouse papers' is smaller than the difference between either and a randomized trial in patients, which does not exist for either peptide.

The 'stacking' claim

Sellers combine the two in oral 'gut repair' capsules and, with GHK-Cu and TB-500, in the KLOW injectable blend that our GLOW and KLOW page takes apart. The pitch is complementary mechanisms: BPC-157 'rebuilds' and KPV 'calms'. It is a tidy story and an untested one. We found no study, in animals or humans, of KPV and BPC-157 given together, so nothing is known about whether they add, interfere or do nothing in combination; the two laboratories that study them have never published on the pair. In practical terms, a blend means two unverified research chemicals in one capsule or syringe, a dose for each chosen by the seller, and no way to attribute a rash, a fever, a flare or a benefit to either one. The arithmetic of the KLOW charts, which deliver about half a milligram each of BPC-157 and KPV per injection, is on the stack page.

What an IBD patient should actually do

If you have ulcerative colitis or Crohn's disease, the question is not KPV or BPC-157; it is what the trials support. The 2025 American College of Gastroenterology guideline grades the options by severity and extent: mesalamine for mild-to-moderate ulcerative colitis, corticosteroids to induce remission in flares, thiopurines, biologics against TNF, integrins and the IL-23 pathway, JAK inhibitors and S1P modulators for moderate-to-severe disease, with the trial quality behind each recommendation stated (Rubin 2025). Those drugs have risks, infection above all, and they come with the scoping, blood tests and follow-up that manage those risks. A research peptide has the same theoretical liabilities, since both of these dampen inflammatory signaling, and none of the management.

Three practical rules follow. Do not stop or substitute prescribed therapy for either peptide; an untreated flare of ulcerative colitis can end in surgery. Tell your gastroenterologist about anything you add, because a research capsule of unknown content is a variable they need to know about when a flare or an abnormal blood test appears. And ask any clinic selling 'gut peptides' the question from our legal tracker: which pharmacy, in which state, on what legal basis? For KPV and BPC-157 in October 2026 there is no good answer. This site does not replace a gastroenterologist, and it is not meant to.

Bottom line

KPV and BPC-157 are the two most-cited 'gut healing' peptides, and they are in the same position: real animal data, no human trial, no approved product anywhere, no legal compounded version in the United States, and an advisory committee vote in July 2026 that FDA has not turned into a rule. BPC-157 has more papers from fewer hands; KPV has fewer papers, more laboratories and a mechanism that explains why it might work by mouth in an inflamed colon. Nobody has studied the two together. For anyone with a diagnosed gut disease, the choice between them is a choice between two research vials, and the treatments that have been tested in people are available on prescription today.

Frequently asked questions

+−Is KPV or BPC-157 better for gut healing?

Neither has been tested in a human with any gut condition, so there is no evidence-based answer. BPC-157 has a much larger rodent literature, mostly from one laboratory in Zagreb, covering stomach ulcers, colitis, fistulas and bowel anastomoses; KPV has a smaller set of mouse colitis studies from three independent groups and a better-defined mechanism, a transporter that is switched on in an inflamed colon. Both are unapproved, neither may be compounded by a US pharmacy as of October 2026, and the treatments with human trials for ulcerative colitis and Crohn's disease are the ones a gastroenterologist prescribes.

+−Can you take KPV and BPC-157 together?

People do, because sellers package them together as oral 'gut' capsules and as the injectable KLOW blend, but no study in animals or humans has tested the combination. The two peptides work by different routes (KPV through the PepT1 transporter and NF-kappa-B, BPC-157 through blood-vessel growth and nitric oxide), so 'synergy' is a hypothesis, and if a blended product causes a reaction there is no way to tell which compound did it. Both are research chemicals with no pharmacy behind them.

+−What are the benefits of BPC-157 with KPV?

The marketed benefits are gut lining repair, less inflammation, relief of ulcerative colitis, Crohn's disease, leaky gut and IBS, and faster healing. None of that has been shown in people for either peptide alone, and nothing has been studied for the pair. In rodents, BPC-157 healed gut injuries and KPV reduced chemically induced colitis; those are the only documented benefits, and they are in mice and rats.

+−Is BPC-157 or KPV legal in the US?

Neither is approved, and neither can be compounded by a licensed pharmacy as of October 2026. Both came off FDA's Category 2 safety-risk list on April 15, 2026, and on July 23, 2026 FDA's advisory committee voted 8-6-1 to recommend each of them for the permitted list, BPC-157 for ulcerative colitis and KPV for wound healing and inflammatory conditions, against the advice of FDA's own staff. FDA has not published a rule for either, so every product sold today is an unapproved drug, and possessing one is not a crime but selling one is.

+−Which has more research, KPV or BPC-157?

BPC-157 by volume: about 220 PubMed papers, nearly all in rodents and most from the group that discovered it, plus three uncontrolled human pilots in knee pain, interstitial cystitis and intravenous safety. KPV has a couple of dozen animal and cell studies, including mouse colitis work from three independent laboratories, and no human study at all. Volume from one laboratory and independence are different kinds of strength, and neither adds up to a human trial.

+−Does oral BPC-157 or oral KPV work better?

Both have a reason to be sold as capsules: BPC-157 is unusually stable in stomach acid and worked in rat drinking water, and KPV is carried into cells by PepT1, the small-intestine peptide transporter that appears in the colon during inflammatory bowel disease. Neither has human oral pharmacokinetic data. A BPC-157 tablet trial registered in 2015 never reported results, and the laboratory that showed oral KPV works in mice later found free KPV needed about 12,000 times the concentration of a colon-targeted nanoparticle version.

+−What should someone with ulcerative colitis or Crohn's disease take instead?

What a gastroenterologist prescribes after assessing severity and extent: mesalamine, corticosteroids for flares, thiopurines, biologics against TNF, integrins and IL-23, JAK inhibitors or S1P modulators, all with randomized-trial evidence and monitoring. Do not stop or substitute prescribed therapy for a research peptide, and tell your clinician about anything you add. This site is not a substitute for that clinician.

Sources

1. StudyDalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008;134:166-78. (2008)
2. StudyKannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:324-31. (2008)
3. StudyKlicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008;108:7-17. (2008)
4. ReviewSikiric P et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012;19:126-32. (2012)
5. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
6. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c; FDA reviewers opposed all four). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
7. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (proposed uses: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing). July 30, 2026. (2026)
8. GuidelineRubin DT et al. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol 2025;120:1187-224. (2025)